AR SB387

Amends Arkansas Code Title 20, Chapter 77 to authorize Arkansas Medicaid coverage for off-label use of drug treatments for pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS).

Defines PANS as a clinically defined disorder characterized by sudden onset of obsessive-compulsive symptoms or eating restrictions accompanied by two or more symptoms of acute behavioral deterioration or motor and sensory changes.

Defines PANDAS as a subset of symptoms affecting children and adolescents within the broader PANS classification.

Requires coverage for off-label drug treatments including intravenous immunoglobulin (IVIG) when prescribed under a treatment plan established by the Postinfectious Autoimmune Encephalopathy Center of Excellence clinic in Arkansas.

Directs the Department of Human Services to apply for any necessary federal waivers, state plan amendments, or other authorizations to implement the coverage requirement.